Analyst consensus rating
Vistagen Therapeutics Analyst Rating: Hold
VTGN is rated Hold by 2 analysts with a $1.00 target. As of 2026-08-24.
Direct answer
Vistagen Therapeutics's consensus rating is Hold.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $1.00.
Forecast evidence checked August 24, 2026.
Get free Vistagen Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.24
- Average price target
- $1.00
- High price target
- $1.00
- Low price target
- $1.00
- Low target gap
- +310.2%
- Target upside
- +310.2%
- High target gap
- +310.2%
- Target range width
- 0%
- Consensus rating
- Hold
- Analysts
- 2
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Vistagen Therapeutics?
Vistagen Therapeutics has a verified Hold consensus. The same dataset has an average price target of $1.00.
How far are Vistagen Therapeutics's low and high targets from the recorded price?
The low target implies +310.2%, while the high target implies +310.2%.
How many analysts are included in Vistagen Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Vistagen Therapeutics's target upside or downside calculated?
The average target of $1.00 is divided by the recorded price of $0.24, then one is subtracted to produce +310.2%. This does not guarantee a future return.
When was Vistagen Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.